🎉 M&A multiples are live!
Check it out!

Eledon Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Eledon Pharmaceuticals and similar public comparables like Pharming, Vivoryon Therapeutics, and Galapagos.

Eledon Pharmaceuticals Overview

About Eledon Pharmaceuticals

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.


Founded

2004

HQ

United States of America
Employees

31

Website

eledon.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$39.2M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Eledon Pharmaceuticals Financials

Eledon Pharmaceuticals has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Eledon Pharmaceuticals achieved revenue of n/a and an EBITDA of -$70.2M.

Eledon Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Eledon Pharmaceuticals valuation multiples based on analyst estimates

Eledon Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$42.6M -$70.2M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$88.0M -$40.3M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Eledon Pharmaceuticals Stock Performance

As of April 15, 2025, Eledon Pharmaceuticals's stock price is $3.

Eledon Pharmaceuticals has current market cap of $178M, and EV of $39.2M.

See Eledon Pharmaceuticals trading valuation data

Eledon Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$39.2M $178M XXX XXX XXX XXX $-0.85

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Eledon Pharmaceuticals Valuation Multiples

As of April 15, 2025, Eledon Pharmaceuticals has market cap of $178M and EV of $39.2M.

Eledon Pharmaceuticals's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Eledon Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Eledon Pharmaceuticals and 10K+ public comps

Eledon Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $39.2M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA -0.6x XXX XXX XXX
P/E -4.9x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Eledon Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Eledon Pharmaceuticals Valuation Multiples

Eledon Pharmaceuticals's NTM/LTM revenue growth is n/a

Eledon Pharmaceuticals's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $2.3M for the same period.

Over next 12 months, Eledon Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Eledon Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Eledon Pharmaceuticals and other 10K+ public comps

Eledon Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth 65% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $2.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Eledon Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Vaccines & Immunotherapies comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Eledon Pharmaceuticals M&A and Investment Activity

Eledon Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Eledon Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Eledon Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Eledon Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Eledon Pharmaceuticals

When was Eledon Pharmaceuticals founded? Eledon Pharmaceuticals was founded in 2004.
Where is Eledon Pharmaceuticals headquartered? Eledon Pharmaceuticals is headquartered in United States of America.
How many employees does Eledon Pharmaceuticals have? As of today, Eledon Pharmaceuticals has 31 employees.
Who is the CEO of Eledon Pharmaceuticals? Eledon Pharmaceuticals's CEO is Dr. David-Alexandre C. Gros, M.D..
Is Eledon Pharmaceuticals publicy listed? Yes, Eledon Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Eledon Pharmaceuticals? Eledon Pharmaceuticals trades under ELDN ticker.
When did Eledon Pharmaceuticals go public? Eledon Pharmaceuticals went public in 2014.
Who are competitors of Eledon Pharmaceuticals? Similar companies to Eledon Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Eledon Pharmaceuticals? Eledon Pharmaceuticals's current market cap is $178M
Is Eledon Pharmaceuticals profitable? Yes, Eledon Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.